Resource will foster innovation in DEM simulation for process industries.
DEM Solutions made available an extensive, searchable, online library of abstracts of peer-reviewed papers on the development and application of discrete element method (DEM) simulation for modeling bulk particle processes, the company announced in a press release.
The resource has been available to DEM Solutions' customers and academic users and is now publicly available. “With growing interest in deploying DEM simulation across many of the manufacturing and process industries, we wanted to open up access to non-customers as well in order to foster innovation and new application areas,” said John Favier, PhD, CEO of DEM Solutions, in the press release.
The DEM Literature Database currently includes abstracts of over 3000 papers and is searchable by title, author, keywords, publisher, and year of publication, including links to publication sources where the full-text papers can be obtained. The database includes papers published from 2001 through early 2013 and will be updated regularly as new papers are made available.
“We want to make it much easier for those in commercial R&D and academic research to find out about the latest DEM developments, as well as to locate previous studies using similar methodology or addressing the same engineering challenges,” said Favier. “Visitors can follow the work of thousands of DEM researchers over the last decade or explore the progression of DEM deployment within an industry vertical or engineering discipline.”
DEM Solutions commented on DEM simulation in the pharmaceutical industry in a recent Pharmaceutical Technology article, “Developments in Pharmaceutical Process Modeling.”
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.